Enrollment Completed in BIOMAG™-LL Clinical Study Evaluating Longer Lengths for Freesolve™ Resorbable Magnesium Scaffold
Business Wire•12/10/2026•06:30 ET
0
Key Highlights
- ➤102 patients enrolled across 14 European centers in BIOMAG™-LL study
- ➤35 mm and 40 mm Freesolve™ scaffolds target coronary lesions up to 38 mm
- ➤BIOMAG™-LL primary endpoint is 12-month Target Lesion Failure rate
- ➤Longer scaffold lengths may reduce permanent implants and scaffold overlap
- ➤35 mm and 40 mm lengths also included in ongoing BIOMAG™-III trial
Expert Statements
Flavio Ribichini, Interventional Cardiologist
“In the increasingly prevalent setting of diffuse coronary artery disease, we want to avoid long, permanent stented segments where possible.”
Flavio Ribichini, Interventional Cardiologist
“The data generated by the BIOMAG™-LL Clinical Study will help determine whether longer Freesolve™ Scaffolds can expand treatment options for patients with longer lesions while supporting the broader evolution of resorbable scaffold therapy.”
Georg Nollert, Vice President Medical Affairs at Teleflex
“We are pleased to announce the successful completion of enrollment in the BIOMAG™-LL Clinical Study.”
Georg Nollert, Vice President Medical Affairs at Teleflex
“The study represents an important step in expanding the Freesolve™ RMS portfolio to address longer coronary lesions while maintaining the performance characteristics of our resorbable magnesium scaffold technology.”
Enrollment Completed in BIOMAG™-LL Clinical Study Evaluating Longer Lengths for Freesolve™ Resorbable Magnesium Scaffold
102 patients enrolled across 14 European centers to assess safety and clinical performance of 35 mm and 40 mm Freesolve™ Resorbable Magnesium Scaffolds in long coronary lesions
Get started
Create a free account to read the full story.